Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO

New Phase 3 Data Evaluating STELARAÂ ustekinumab Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis Featured in Plenary Session The Janssen Pharmaceutical Companies of Johnson & Johnson today ...